Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer

Former Genentech CEO Ian Clark will guide Kyverna's vision to transform the treatment of autoimmune diseases through engineered cell therapies Seasoned pharmaceutical executive Karen Walker will lead technical development of Kyverna's T-cell therapies ... Biopharmaceuticals, Personnel Kyverna Therapeutics, cell therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

This study evaluated SARS-CoV-2-specific humoral and cellular responses after vaccination with a two-dose schedule in a Crohn’s disease patient treated with Infliximab (10 mg/kg); we included comparisons with a monozygotic twin. The results showed that the Crohn’s disease’s twin (twin 2) had no antibody detection and reduced activation of CD4+ T cell responses, unlike the twin without the autoimmune disease (twin 1). Twin 2 developed antigen-specific central memory CD8+ T-cells and IFNγ production after the second dose of COVID-19 vaccination, similar to twin 1. These findings elucidated the role of...
Source: Viruses - Category: Virology Authors: Tags: Communication Source Type: research
The objective of this study was to determine predictors of hospitalization for COVID-19 patients from an ARD community cohort.MethodsA real setting longitudinal study (March to November 2020) in an ARD community cohort was carried out. Potential predictors of hospitalization for COVID-19 examined included (1) sociodemographic variables (age, gender, education, tobacco use, socioeconomic status, and co-inhabitants), (2) comorbidities, (3) time to COVID-19 diagnosis, and (4) ARD ’s features: clinical (disease type, disease duration, activity), treatment [corticosteroids use/doses, use of synthetic DMARDs (cDMARDs, tsDM...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
AbstractRheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease affecting not only the synovial joints but also multiple extra-articular sites, including ankle and foot soft tissue. Hindfoot abnormalities usually follow those in the forefoot, with up to 4 out of 10 patients experiencing talalgia during their disease course. Enthesophytosis, retrocalcaneal bursitis, and plantar fasciitis are among the most common etiologies, while heel fat pad abnormalities like subcalcaneal bursitis are rare. Here, we report two cases of subcalcaneal bursitis, and the first case of heel fat pad and subcalcaneal bursa herniat...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Conditions:   Prolonged Anticoagulation;   Venous Thromboembolic Disease;   Autoimmune Hemolytic Anemia Interventions:   Drug: treatment  " intervention " ;   Drug: treatment  " standard " ;   Biological: biological assessment Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: - Category: Research Source Type: clinical trials
AbstractEffective immunomodulation of T-cell responses is critical in treating both autoimmune diseases and cancer. Our previous studies have demonstrated that secretomes derived from control or methoxypolyethylene glycol mixed lymphocyte alloactivation assays exerted potent immunomodulatory activity that was mediated by microRNAs (miRNA). The immunomodulatory effects of biomanufactured miRNA-based allo-secretome therapeutics (SYN, TA1, IA1 and IA2) were compared to Pan T-cell activators (PHA and anti-CD3/CD28) and lymphocyte alloactivation. The differential effects of these activation strategies on resting peripheral bloo...
Source: Archivum Immunologiae et Therapiae Experimentalis - Category: Allergy & Immunology Source Type: research
This study provides insights into the pathogenic mechanisms of LN and that CRAC channel could serve as a potential therapeutic target for LN.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Future Microbiology, Ahead of Print.
Source: Future Microbiology - Category: Microbiology Authors: Source Type: research
We described a patient who developed four limb distal paraesthesia, postural instability, and facial  diplegia, ten days after vaccination with ChAdOx1 nCoV-19 (ABW1277). The electrophysiological findings were compatible with acute demyelinating motor polyneuropathy (Guillain-Barrè syndrome).DiscussionWe therefore want to describe a temporal correlation between administration of ChAdOx1 nCoV-19  (ABW1277) vaccine and GBS without evidence of other predisposing infectious or autoimmune factors. This paper aims to highlight the importance of pharmacovigilance and subsequent reports will be needed&nb...
Source: Neurological Sciences - Category: Neurology Source Type: research
Source: Neurological Sciences - Category: Neurology Source Type: research
Conditions:   Immune Thrombocytopenia (ITP);   Cold Agglutinin Disease (CAD) Intervention:   Drug: Iptacopan Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Autoimmune Disease | Pharmaceuticals